Results 141 to 150 of about 6,938,572 (266)

David Reeve, "To remain myself; The history of Onghokham"

Wacana: Journal of the Humanities of Indonesia
Dick van der Meij
doaj   +1 more source

Case-control study of risk factors for abscess development following hepatitis B vaccination in children in Timor-Leste, 2024. [PDF]

PLoS One
da Silva Marques M, de Neri Machado F, Amaral Mali M, da Costa Sarmento N, Soares D, Gama Soares N, de Alexandria Barros C, Guterres Babo LNM, da C Silva AA, Adão Mendonça E, Jesus da Silva N, Barreto Dos Santos N, Neves MAAM.   +12 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Test-retest reliability and sensitivity of horizontal jump inter-limb asymmetry in youth soccer players across maturity stages. [PDF]

PLoS One
Hammami R, Negra Y, Ceylan HI, Selmi W, Morgans R, González-Fernández FT, Bragazzi NL.   +6 more
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Benign maculopapular rash following dengue vaccination with Butantan-DV: a case series. [PDF]

An Bras Dermatol
Carvalho TH, Monteiro Neto AJO, Bonini IFDSM, Oliveira MZM, Jorge MFS, Miot HA.   +5 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Provincial variability in congenital heart disease prevalence in Argentina, 2014-2019: A population-based analysis from national registry data. [PDF]

PLOS Glob Public Health
Vita MC, Fantozzi N, Méndez Ortiz F, Di Lullo L, Kokal R, Peralta S, Di Lalla S.   +6 more
europepmc   +1 more source

Preparation of manuscript

Journal of Medical Physics, 2010
openaire   +3 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source